Dr. Kevin Hay
Dr. Kevin Hay is an Assistant Professor at the University of British Columbia and Medical Director of the Clinical Cell Therapy (CCT) and Conconi Family Immunotherapy Laboratory. He is also a clinical scientist and leads his own research group at Terry Fox Laboratory.
Education
Dr. Hay received a Bachelor of Science with honours at Trinity Western University in 2005. Then, he obtained a Master of Science in Immunology at the University of Manitoba (2008) where he also obtained an MD degree in 2011. After that, Dr. Hay completed a medical residency in Internal Medicine (2014) and a fellowship in hematology (2016). Dr. Hay was awarded the UBC Clinician Investigator scholarship to pursue a postdoctoral fellowship in cellular immunotherapy at the Fred Hutchinson Cancer Research Center in Seattle, Washington.
Research and Career
Dr. Kevin Hay is a clinical scientist and has his own lab at Terry Fox Laboratory. His lab is focused on Chimeric antigen receptor T (CAR-T) cell therapy. They are trying to develop new CAR-T cell therapy with less toxicity and more efficacy [4][5]. Also, Dr. Kevin Hay's lab is trying to develop new CAR-T cell therapy for other malignancies, such as myeloma. With Dr. Robert Holt and Dr. Brad Nelson, Dr. Kevin Hay is a key investigator of the ongoing Canadian Project: Phase I/II Multicenter Clinical Trial of a Novel Single Domain (sd)CD-22-specific Camelid-derived Chimeric Antigen Receptor (CAR) T-cell Therapy.[6][7][8] Also, Dr. Hay is one of the members of the group conducting the first trial that uses Canadian-made CAR T cells.[9]
Dr. Kevin Hay is a director of Clinical Cell Therapy (CCT). Under his supervision, the CCT laboratory is designing and implementing new therapies for patients in the Leukemia/Bone Marrow Transplant program of BC. Currently, several protocols are being elaborated by the group, including CAR-T cell therapy infusion and manufacturing eye drops for patients with graft-versus-host disease.[10]
References
[1] [2] [3] [4] [5] [6] [7] [8] [9] [10]
- ↑ https://www.linkedin.com/in/kevin-hay-43bb1398/?originalSubdomain=ca
- ↑ https://hematology.med.ubc.ca/faculty/khay/
- ↑ https://www.bccrc.ca/dept/tfl/labs/hay-lab
- ↑ Hay, K.A. (2018), Cytokine release syndrome and neurotoxicity after CD19 chimeric antigen receptor-modified (CAR-) T cell therapy. Br J Haematol, 183: 364-374. https://doi.org/10.1111/bjh.15644
- ↑ Brown, Kevin et al. “Innovations in cancer immunotherapy: chimeric antigen receptor T-cell therapy (CAR-T).” CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne vol. 193,33 (2021): E1300-E1302.
- ↑ https://systematicreviewsjournal.biomedcentral.com/articles/10.1186/s13643-021-01588-7
- ↑ https://biocanrx.com/es15-hay
- ↑ Adeel, K., Fergusson, N.J., Shorr, R. et al. Efficacy and safety of CD22 chimeric antigen receptor (CAR) T cell therapy in patients with B cell malignancies: a protocol for a systematic review and meta-analysis. Syst Rev 10, 35 (2021)
- ↑ https://www.vchri.ca/stories/2021/08/31/canadian-first-car-t-cell-treatment-adult-leukemia-and-lymphoma
- ↑ https://www.bccrc.ca/dept/tfl/services/clinical-cell-therapy
This article "Dr. Kevin Hay" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:Dr. Kevin Hay. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.
